Background
==========

IgA nephropathy, the most common primary glomerulonephritis worldwide, is associated with a substantial risk of progression to end-stage renal failure (ESRF) \[[@B1]\]. The disease runs a highly variable clinical course. A subgroup of IgAN with tubulointerstitial damage is often associated with the most rapid progression to ESRF \[[@B2]\]. We have previously documented that mesangial IgA deposition induces local release of pro-inflammatory cytokines leading to glomerular inflammation \[[@B3],[@B4]\]. The renin-angiotensin system (RAS) is strongly involved in the development of progressive renal fibrosis with local AngII hyperactivity occurring in IgAN \[[@B5]-[@B7]\]. We had revealed that IgA from IgAN patients was capable of up-regulating the TGF-β production *via*increased AngII release by HMC following binding to pIgA \[[@B8]\]. We further demonstrated altered expression of mesangial and tubular angiotensin receptors in response to raised intra-renal AngII in IgAN \[[@B3],[@B4],[@B9]\]. Although these data shed light on the importance of AngII and RAS in the pathogenesis of IgAN, a possible link between the aldosterone system and IgAN remains lacking. Aldosterone is an important mediator bearing injurious actions of the RAAS in chronic heart failure and renal disease \[[@B10]-[@B13]\]. Aldo promotes fibrosis and vascular toxicity in experimental animal models \[[@B14]-[@B16]\]. The specific action of Aldo is mediated through the mineralocorticoid receptor (MR) in the presence of 11ß-hydroxysteroid dehydrogenase type II (11ß-HSD2) \[[@B13]\]. In humans, exogenous aldosterone increases circulating interleukin-6 (IL-6) concentrations and MR antagonism attenuates AngII-induced IL-6 increase \[[@B17]\], suggesting that endogenous aldosterone may contribute to the pro-inflammatory effects of AngII. AngII inhibition combined with Aldo blockade effectively reduces proteinuria in human CKD \[[@B18]\]. All these evidences suggest that Aldo may also be involved in the pathophysiology of IgAN.

Methods
=======

Materials
---------

Reagents used for cell culture were obtained from Life Technologies (Rockville, MD, USA). Monoclonal anti-MR was obtained from Abcam (Cambridge, MA, USA). Rabbit anti-11ß-HSD2 was obtained from Cayman Chemical (Ann Arbor, MI, USA). Goat anti-CYP11B2, rabbit polyclonal anti-AT1R (AT1R) and AngII receptor subtype-II (AT2R) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-cleaved poly-(ADP-ribose)-polymerase (PARP) was obtained from Cell Signaling Technology (Beverly, CA, USA). Monoclonal anti-actin was obtained from Neomarkers (Fremont, CA, USA). F(ab\')~2~fragment of Alexa Fluor 488-conjugated goat anti-mouse, donkey anti-goat, goat anti-rabbit immunoglobulin G (IgG) antibodies were obtained from Invitrogen Ltd. (Paisley, UK). The Envision Plus System was obtained from Dako (Carpinteria, CA, USA). Peroxidase labeled anti-goat antibody was obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). 4\',6\'-diamidino-2-phenylindole hydrochloride (DAPI) was obtained from Molecular Probe (Eugene, OR, USA). Human total kidney RNA was obtained from Life Technologies Corporation (Carlsbad, CA, USA). Angiotensin II, aldosterone, angiotensin-converting enzyme inhibitor (ACEI), eplerenone, AngII receptor antagonist and other chemicals were obtained from Sigma (St. Louis, MO, USA).

Study Population
----------------

The study protocol was approved by the Research Ethics Committee of the University of Hong Kong and was carried out in accordance with the principles of Declaration of Helsinki. Twenty-seven Chinese patients (12 male and 15 female) with clinical and renal immunopathological diagnosis of primary IgAN were studied. Fifty milliliters of blood were collected from each studied subject at clinical quiescence (no macroscopic hematuria with urinary erythrocyte count \< 10,000/ml in un-centrifuged urine). The serum was isolated and frozen at -20°C until for isolation of pIgA1. Twenty-two healthy subjects (10 male and 12 female), comparable in age and race, with no microscopic hematuria or proteinuria, were recruited as controls.

Purification of pIgA
--------------------

Jacalin binding protein (JBP) was purified using a jacalin-agarose affinity column and pIgA was fractionated by the FPLC as described previously \[[@B19]\].

Cell Culture and Preparation of Conditioned Medium
--------------------------------------------------

Isolation and characterization of HMC and PTEC were performed as previously described \[[@B4],[@B20]\]. Growth arrested HMC were cultured in six-well culture plates (1 × 10^6^cells per well) with culture medium containing 0.5% FBS and pIgA (final concentration 0.5 mg/ml) isolated from patients with IgAN or controls for 48 hours. The conditioned medium (IgA-HMC medium) after culture were collected and kept frozen at -70°C until used. Conditioned medium from HMC cultured without the addition of IgA preparation was used as plain medium control.

Expression of MR, 11β-HSD2 or CYP11B2 in HMC and PTEC
-----------------------------------------------------

HMC or PTEC were cultured with pIgA (0.5 mg/ml) from controls or IgAN patients, or IgA-HMC medium from IgAN patients (for PTEC only), for 6 h (for RNA expression) or 24 h (for protein determination). The expression of MR, 11β-HSD2 and CYP11B2 were determined by qPCR and immunoblotting. Expression of CYP11B2 in HMC or MR in PTEC was also examined using immunofluorescence staining.

Cell Culture Experiments
------------------------

To determine the dose- or time-course of CYP11B2 expression or Aldo synthesis by HMC, growth arrested HMC were cultured with pIgA (0.125 to 2 mg/ml) or AngII (10^-12^to 10^-8^M) for 6 h (for RNA expression) or 48 h (for protein or Aldo assay); or with pIgA (0.5 mg/ml) or AngII (10^-10^M) for 6 h to 96 h. To determine the dose course of angiotensinogen and ACE expression or AngII release by HMC, growth arrested HMC were cultured with Aldo (10^-12^to 10^-8^M) for 6 h (total RNA purification) or 48 h (for AngII assay). To examine whether there was synergistic effect of AngII and Aldo on TGF-β synthesis by HMC, growth arrested HMC were cultured with different concentrations of Aldo, AngII or their combination (10^-12^to 10^-8^M) for 48 h. For studying the role of MR and AT1R in pIgA induced TGF-β synthesis by HMC, HMC were pre-incubated with losartan (100 mM) or/and eplerenone (10 μM) one hour before addition of pIgA.

To examine the differential effect of pIgA, conditioned medium, AngII and Aldo on expression of MR or AT2R, ROS generation and NADPH oxidase activity by PTEC, growth arrested PTEC were cultured with (i) pIgA (0.5 mg/ml) from IgAN patients; (ii) 4 fold diluted IgA-HMC medium prepared from controls or IgAN patients; (iii) Aldo (10^-10^M) or (iv) AngII (10^-10^M) for 6 h (for mRNA) or 48 h (for protein). PTEC were also pre-incubated with losartan (100 mM), PD123319 (10 μM), eplerenone (10 μM) or their combinations one hour before experiments for studying the role contributed by MR, AT1R or AT2R in ROS generation and caspase 3 activity induced by conditioned medium or AngII.

To determine the time-course of cleaved PARP or caspase 3 activity in PTEC, PTEC were cultured with (i) pIgA (0.5 mg/ml) from IgAN patients; (ii) 4 fold diluted IgA-HMC medium prepared from controls or IgAN patients; (iii) Aldo (10^-10^M) or (iv) AngII (10^-10^M) for different time points For dose-course study, PTEC were cultured with various concentrations or dilutions of (i) pIgA from IgAN patients; (ii) IgA-HMC from controls or IgAN patients; (iii) Aldo or (iv) AngII for 48 h.

Immunohistochemistry Examination
--------------------------------

Renal tissues were obtained from eight normotensive patients with mild IgAN (grade 1) consecutively admitted for diagnostic renal biopsy with the presentation of microscopic haematuria. They had not previously received angiotensin-converting enzyme inhibitor or Ang II receptor subtype-1 (ATR1) antagonist. Control renal tissues were obtained from the intact pole of kidneys removed for single circumscribed tumor in seven normotensive subjects (comparable in age, sex and race). Glomerular and tubular expression of MR, 11β-HSD2 and CYP11B2 were detected by immunoperoxidase staining using specific antibodies. The bound monoclonal anti-MR or rabbit polyclonal anti-11β-HSD2 antibodies were visualized in brown using the Dako Envision Plus System. The bound goat anti-CYP11B2 antibodies were detected with peroxidase labeled anti-goat antibodies and visualized in brown using 3,3\'-diaminodbenzidine (DAB). Negative controls were done with primary antibodies absorbed with relevant antigens before the first incubation. Two renal pathologists without prior knowledge of clinical or laboratory data evaluated the expression of MR, 11β-HSD2 and CYP11B2 using an arbitrary 0-5+ scale \[[@B4],[@B9]\].

Immunoblotting
--------------

HMC or PTEC were harvested and dissolved in protein extraction buffer containing protease inhibitor cocktails. Total protein from HMC (50 μg) or PTEC (10 μg) was electrophoresed through a 15% SDS-PAGE and then transferred to the polyvinylidene fluoride (PVDF) membrane. The membrane was incubated overnight with anti-CYP11B2 (1:1000), anti-AT2R (1:1000), anti-MR (1:1000) or anti-actin (1:1000) antibody in PBS-Tween before reacting with appropriate peroxidase-labeled secondary antibodies (Dako, Kyoto, Japan). The reaction was detected with ECL plus chemiluminescent detection reagent (Amersham Pharmacia Biotech, Uppsala, Sweden). The images were scanned and the density of the bands was quantitated using the ImageQuant software (Molecular Dynamic, Sunnyvale, CA, USA). The densitometric results were reported as average arbitrary integrated values (units) after normalization with the average arbitrary integrated values of the actin signal.

Detection of Cleaved PARP Expression in HMC and PTEC
----------------------------------------------------

Cell extracts were prepared from HMC or PTEC. Early apoptosis was detected by immunoblotting using monoclonal anti-PARP antibody (1:500) that recognized the 89 kDa cleaved PARP fragment. The membrane was then washed and incubated for 2 hours at room temperature with a peroxidase-labeled goat anti-mouse immunoglobulin (Dako, Kyoto, Japan). The reaction was quantitated as described in the previous section.

Real-time RT-PCR
----------------

Real-time RT-PCR was performed as previously described \[[@B21]\]. Primer sequences and gene bank accession numbers are listed in Table [1](#T1){ref-type="table"}. Data obtained were analyzed using the comparative *C*~T~(cycle threshold) method.

###### 

Primer sequences for qPCR

  Gene       Forward primer sequences      Reward primer sequences
  ---------- ----------------------------- ----------------------------
  CYP11B2    5\'-TACAGGTTTTCCTCTACTCG      5\'-AGATGCAAGACTAGTTAATC
  11β-HSD2   5\'-GGCCACAATGAAGTAGTTGC      5\'-CTCCCCACAGTCACGATG
  ANG        5\'-CTGCAAGGATCTTATGACCTGC    5\'-TACACAGCAAACAGGAATGGGC
  ACE        5\'-CCGAAATACGTGGAACTCATCAA   5\'-CACGCGTCCCCTGCATCTACA
  MR         5\'-TCTGACTCTGGGAGCTCCGT      5\'-TCCTCCTAGACATGAGCTGC
  AT2R       5\'-AGTAAGCACAGAATTCAAAG      5\'-AGTAAAGAATAGGAATTGCAT
  GAPDH      5\'-CTCTCTGCTCCTCCTGTTCGAC    5\'-TGAGCGATGTGGCTCGGCT

Determination of TGF-β, AngII or Aldo in Supernatant from Cultured HMC
----------------------------------------------------------------------

TGF-β in supernatant from HMC culture was determined with the ELISA kits from R&D Systems (Minneapolis, MN, USA). The detection sensitivity was 32 pg/ml and the inter-batch coefficients of variation was 6.5%. AngII and Aldo were measured by an enzyme immunoassay kit (Cayman) according to the manufacturer\'s instruction. The minimum detectable concentration for AngII and Aldo was 1 and 7.8 pg/ml respectively with corresponding intra-assay coefficient of variation of 7 and 12.5%.

Quantification of Apoptosis, Determination of ROS and NADPH Oxidase Activity
----------------------------------------------------------------------------

Activation of caspase 3 in PTEC cultured with IgA-HMC conditioned medium was determined using the caspase 3 activity fluorometric immunosorbant enzyme assay kit (Roche Diagnostics) according to manufacturer\'s protocol. ROS generation was measured with the fluoroprobe carboxymethyl-H~2~-dichlorofluorescein diacetate. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was determined using an assay based on the chemiluminescence of lucigenin (bis-N-methylacridinium nitrate).

Statistics
----------

All data were expressed as means ± standard deviation (SD) unless otherwise specified. Statistical difference was analyzed with multivariate ANOVA for repeated measures. All p-values quoted are two-tailed and the significance is defined as p \< 0.05.

Results
=======

Expression of CYP11B2 and 11β-HSD2 in HMC and Their Regulation by pIgA
----------------------------------------------------------------------

Cultured HMC expressed mRNA for the CYP11B2 and 11β-HSD2 constitutively and pIgA from IgAN patients up-regulated the gene (Figure [1A](#F1){ref-type="fig"}) and protein (Figure [1B](#F1){ref-type="fig"}) expression of CYP11B2 (p \< 0.05), without altering the mRNA expression of 11β-HSD2. Up-regulation of CYP11B2 expression in HMC by pIgA from IgAN patients was confirmed by immunofluorescence staining (Figure [1C](#F1){ref-type="fig"}). A time- and dose-dependent increase in CYP11B2 expression in HMC was only demonstrated with pIgA from IgAN patients, but not with control pIgA (Figure [2](#F2){ref-type="fig"}).

![**Increased expression of CYP11B2 in HMC cultured with pIgA**. (A) There was increased expression of CYP11B2 mRNA and (B) CYP11B2 protein, but not 11β-HSD2, by HMC cultured with pIgA from patients (IgAN, n = 27) as compared to that of the controls (Control, n = 22). The results represent the mean ± SD. (C) Increased expression of CYP11B2 (arrow) in HMC was confirmed by immunofluorescence staining (magnification × 200).](1479-5876-9-169-1){#F1}

![**Dose- and time-dependent CYP11B2 expression in HMC**. (A) Significant up-regulation of CYP11B2 mRNA expression and (B) CYP11B2 protein synthesis by HMC exposed to pIgA from IgAN patients (IgAN), but not with pIgA from controls (Control). (C) HMC cultured with pIgA (0.5 mg/ml) from IgAN, but not with pIgA from controls, exhibited an time-dependent increase of CYP11B2 mRNA expression (from 6 h, peaked at 12 h) and (D) CYP11B2 protein synthesis (from 24 h peaked at 48 h). The results represent the mean ± SD from five individual experiments. \* signifies p \< 0.05 when compared with data from HMC cultured in plain medium or data from time zero.](1479-5876-9-169-2){#F2}

Aldo Up-regulated Mesangial Release of AngII
--------------------------------------------

Polymeric IgA from IgAN patients but not with pIgA from controls, at concentration \> 0.25 mg/ml significantly increased the release of Aldo by HMC in a dose dependent manner (Figure [3A](#F3){ref-type="fig"}). At a concentration of 0.5 mg/ml, only pIgA from IgAN patients induced a time-dependent increase of Aldo in cultured HMC (Figure [3B](#F3){ref-type="fig"}). Exogenous AngII increased the Aldo release and CYP11B2 protein expression in a dose- and time-dependent manner (Figures [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}). Aldo at concentration \> 10^-11^M increased the release of AngII and gene expression of angiotensinogen and ACE by HMC (Figure [4A](#F4){ref-type="fig"}).

![**Dose- and time-dependent Aldo release and CYP11B2 expression in HMC**. (A) Significant increase in Aldo release by HMC exposed to increasing concentration of pIgA from IgAN patients. (B) HMC cultured with pIgA (0.5 mg/ml) from IgAN patients, exhibited time-related increase in Aldo release (from 12 h, peaked at 48 h). (C) AngII induced Aldo release (at concentration \> 10^-12^M) and CYP11B2 protein synthesis (at concentration \> 10^-11^M) from HMC. (D) AngII (10^-10^M) induced time-related increase of Aldo release and CYP11B2 protein synthesis in HMC. The results represent the mean ± SD from five individual experiments. \* signifies p \< 0.05 when compared with data from HMC cultured in plain medium or data from time zero.](1479-5876-9-169-3){#F3}

![**Effect of Aldo or pIgA on TGF-β synthesis and RAS of HMC**. (A) Aldo at concentration \>10^-11^M increased the mRNA expression of angiotensinogen and ACE, and AngII release by HMC. (B) AngII or Aldo at concentration \>10^-11^M increased TGF-β synthesis by HMC. AngII and Aldo showed synergistic effect on TGF-β synthesis by HMC. \* signifies p \< 0.05 when compared with data from control without Aldo or AngII. (C) Pre-incubation with losartan (100 mM) or eplerenone (10 μM) one hour before cultured with pIgA from IgAN patients partially reduced the pIgA-induced TGF-β synthesis by HMC. Combining losartan and eplerenone completely abolished the increased TGF-β synthesis by pIgA. The AngII effect on TGF-β synthesis was blocked by losartan and the Aldo effect blocked by eplerenone; with complete normalization of TGF-β synthesis with the presence of both blockers. \*\* and \* signify p \< 0.01 and p \< 0.05 respectively when compared with data from HMC cultured with pIgA from controls (Control). \#\# and \# signify p \< 0.01 and p \< 0.05 respectively when compared with data from HMC pre-incubated with both inhibitors. The results represent the mean ± SD from five individual experiments.](1479-5876-9-169-4){#F4}

Role of Aldo and AngII in Regulation of TGF-β Synthesis by HMC
--------------------------------------------------------------

AngII and Aldo at concentration \>10^-11^M individually increased TGF-β synthesis by HMC with synergistic effect (Figure [4B](#F4){ref-type="fig"}). Pre-incubation of HMC with either losartan or eplerenone partially reduced the pIgA-induced TGF-β synthesis by HMC (Figure [4C](#F4){ref-type="fig"}). The increased mesangial TGF-β synthesis induced by pIgA was completely abolished with dual blockade of losartan and eplerenone (Figure [4C](#F4){ref-type="fig"}).

Expression of MR, but not CYP11B2 or 11β-HSD2 by PTEC
-----------------------------------------------------

Mineralocorticoid receptor mRNA was constitutively expressed in PTEC, but not for mRNA of CYP11B2 or 11β-HSD2 (Figure [5A](#F5){ref-type="fig"}). There was no induction of CYP11B2 or 11β-HSD2 gene expression in PTEC cultured with pIgA or conditioned medium from HMC incubated with pIgA from IgAN patients (IgA-HMC medium) (data not shown). Immunofluorescence staining confirmed the expression of MR in the resting PTEC (Figure [5B](#F5){ref-type="fig"}).

![**Expression of MR, 11β-HSD2 or CYP11B2 in cultured HMC, PTEC and kidney biopsies**. (A) HMC expressed MR, 11β-HSD2 and CYP11B2 mRNAs and PTEC expressed only MR mRNA. Result was expressed as the mean fold change ± SD (related to the mean *C*~T~value from positive control using purified kidney total mRNA) from five individual experiments. (B) Demonstration of MR expression (arrows) in cultured PTEC by immunofluorescence staining (magnification × 200). (C). Detection of MR, 11β-HSD2 and CYP11B2 in kidney biopsies from IgAN patients and controls. Immunoreactive MR was located in both the glomeruli and tubules. Signal from immunoreactive 11β-HSD2 and CYP11B2 was located in glomeruli but not tubules (magnification × 200). Compared to staining results in control biopsies, increased (D) glomerular CYP11B2 staining and (E) tubular MR staining in IgAN patients were semi-quantified using a five-point scale.](1479-5876-9-169-5){#F5}

Expression of MR, CYP11B2 or 11β-HSD2 in Human IgAN
---------------------------------------------------

Data on the expression of MR, CYP11B2 or 11β-HSD2 in cultured HMC or PTEC were further confirmed by immunohistochemical staining in kidney biopsies from patients with IgAN (Figure [5C](#F5){ref-type="fig"}). When compared with the staining results of the control biopsies, there was significantly increased expression of glomerular CYP11B2 and tubular MR in patients with IgAN (Figures [5D](#F5){ref-type="fig"} and [5E](#F5){ref-type="fig"}).

Regulation of MR and AT2R expression in PTEC
--------------------------------------------

Both exogenous AngII and IgA-HMC medium prepared from IgAN patients significantly increased the expression of MR and AT2R in PTEC (Figures [6A](#F6){ref-type="fig"} to [6D](#F6){ref-type="fig"}) as compared with plain medium. The AT2R antagonist, PD123319, effectively abolished the enhanced expression of MR (Figure [7](#F7){ref-type="fig"}). In contrast, neither losartan nor eplerenone exhibited any inhibitory action.

![**Effect of pIgA, IgA-HMC conditioned medium, AngII and Aldo on the expression of MR or AT2R**. Growth arrested PTEC was cultured with (i) pIgA (IgA, 0.5 mg/ml) from IgAN patients; (ii) 4 fold diluted IgA-HMC medium prepared from controls or IgAN patients; (iii) Aldo (10^-10^M) or (iv) AngII (10^-10^M). Both the exogenous AngII and IgA-HMC medium prepared from IgAN patients significantly increased the expression of (A) MR mRNA, (B) MR protein, (C) AT2R mRNA and (D) AT2R protein as compared with PTEC cultured with plain medium control (\*\* signifies p \< 0.01). The results represent the mean ± SD from five individual experiments.](1479-5876-9-169-6){#F6}

![**The effect of MR, AT1R or AT2R blockade on IgA-HMC medium or AngII induced MR or AT2R expression**. PD123319 effectively abolished the up-regulation of MR and AT2R receptor mRNA (A) or protein expression (B & C) by IgA-HMC medium from IgAN patients (medium-IgA) or AngII. Neither losartan nor eplerenone altered these receptors expression in PTEC. \* and \*\* signify p \< 0.05 and p \< 0.01 respectively when compared with data from PTEC cultured in plain medium. The results represent the mean ± SD from five individual experiments.](1479-5876-9-169-7){#F7}

AngII, Aldo or IgA-HMC Medium from IgAN Patients Induced Apoptosis in PTEC
--------------------------------------------------------------------------

PTEC cultured with Aldo (10^-10^M), AngII (10^-10^M) or 4-fold diluted IgA-HMC medium prepared from IgAN patients, induced cellular apoptosis as indicated by time-and dose-related up-regulation of cleaved PARP expression (Figures [8A](#F8){ref-type="fig"} and [8B](#F8){ref-type="fig"}) and caspase 3 activity (Figures [9A](#F9){ref-type="fig"} and [9B](#F9){ref-type="fig"}). Similar findings were not observed with conditioned medium prepared from controls or direct culture with pIgA from IgAN patients. The induced apoptosis in PTEC was associated with increased reactive oxygen species (ROS) generation and NAPDH oxidase activity (Figures [10A](#F10){ref-type="fig"} and [10B](#F10){ref-type="fig"}). The ROS generation and caspase 3 activity induced by Aldo, AngII or IgA-HMC medium prepared from IgAN patients were partially suppressed by PD123319 or eplerenone and completely abolished with combined use of PD123319 and eplerenone (Figure [11](#F11){ref-type="fig"}). AT1R blockade with losartan exhibited no suppressive effect.

![**Time- and dose-related expression of cleaved PARP by PTEC**. (A) Up-regulation of cleaved PARP expression by PTEC cultured with Aldo (10^-10^M), AngII (10^-10^M) or 4 fold diluted IgA-HMC medium prepared from IgAN patients (medium-IgAN). Similar up-regulation was not observed with IgA-HMC medium from controls (medium-Ctl) or pIgA alone (IgA). (B) Dose-dependent up-regulation of cleaved PARP expression by PTEC cultured with Aldo, AngII or IgA-HMC medium prepared from IgAN patients. \* and \*\* signify p \< 0.05 and p \< 0.01 respectively when compared with data from time zero or from PTEC cultured in plain medium. The results represent the mean ± SD from five individual experiments.](1479-5876-9-169-8){#F8}

![**Time- and dose-related assay of caspase 3 activity in PTEC**. (A) Up-regulation of caspase 3 activity by PTEC cultured with Aldo (10^-10^M), AngII (10^-10^M) or 4 fold diluted IgA-HMC medium prepared from IgAN patients (medium-IgAN); Similar up-regulation was not observed with IgA-HMC medium from controls (medium-Ctl) or pIgA alone (IgA). (B) Dose-dependent up-regulation of caspase 3 activity by PTEC cultured with Aldo, AngII or IgA-HMC medium prepared from IgAN patients. \* and \*\* signify p \< 0.05 and p \< 0.01 respectively when compared with data from time zero or from PTEC cultured in plain medium. The results represent the mean ± SD from five individual experiments.](1479-5876-9-169-9){#F9}

![**ROS generation and NADPH oxidase activity by PTEC**. (A) Up-regulation of ROS generation and (B) NADPH oxidase activity by PTEC cultured with Aldo (10^-10^M), AngII (10^-10^M) or 4 fold diluted IgA-HMC medium prepared from IgAN patients (IgAN); Similar up-regulation was not observed with IgA-HMC medium from controls (Ctl) or pIgA alone (IgA). \*\* signify p \< 0.01 when compared with data from PTEC cultured in plain medium. The results represent the mean ± SD from five individual experiments.](1479-5876-9-169-10){#F10}

![**The effect of MR, AT1R or AT2R blockade in ROS generation and caspase 3 activity by PTEC**. (A) Individual use of MR, AT1R or AT2R antagonist failed to effectively inhibit the up-regulation of ROS generation and (B) caspase 3 activity by PTEC cultured with Aldo (10^-10^M), AngII (10^-10^M) or 4 fold diluted IgA-HMC medium prepared from IgAN patients (medium-IgAN). Abolishment of up-regulated ROS generation and caspase 3 activity by PTEC was only achieved by combining PD123319 and eplerenone. \* and \*\* signify p \< 0.05 and p \< 0.01 respectively when compared with data from HMC cultured with plain medium control. \#\# and \# signify p \< 0.01 and p \< 0.05 respectively when compared with data from HMC corresponding activator without pre-incubation of any receptor antagonist. The results represent the mean ± SD from five individual experiments.](1479-5876-9-169-11){#F11}

Discussion
==========

In this study, *in vitro*culture models of HMC and PTEC were used to examine Aldo synthesis by pIgA directly or through glomerular-tubular communications. The possible role of Aldo on PTEC injury and its interaction with AngII in IgAN was also elucidated. The RAS has been implicated in the development of progressive glomerulosclerosis in diabetic and non-diabetic nephropathy \[[@B22],[@B23]\]. We had previously demonstrated an increased expression of renin and TGF-β by HMC incubated with pIgA from IgAN patients \[[@B8]\]. Polymeric IgA from these patients also up-regulated the Smad activity in HMC which was readily suppressed with captopril or losartan, supporting a pathogenetic role of pIgA1 in IgAN through up-regulation of the RAS and TGF-β. Growing evidence from experimental and clinical studies indicates that increased Aldo is an independent contributor to arterial injury and nephropathy \[[@B24]\]. Both human and rat mesangial cells produce Aldo in culture \[[@B25],[@B26]\]. Exogenous Aldo significantly increased fibronectin production by mesangial cells \[[@B26]\]. Renal TGF-ß and fibronectin are increased in Dahl salt-sensitive rat with heart failure (DSHF rat) in association with the development of glomerulosclerosis \[[@B27]\]. Aldo blocker significantly suppressed renal TGF-ß expression in DSHF rat with reduced glomerulosclerosis. *In vivo*study also showed Aldo administration *per se*induced TGF-ß release and organ fibrosis independent of blood pressure \[[@B28]\]. In the present study, we demonstrate that Aldo may initiate and amplify injury to HMC upon activation by pIgA in both paracrine and endocrine manner. We also reveal a vicious cycle between pIgA-induced AngII and Aldo amplifying the TGF-β synthesis *via*binding to AT1R and MR in cultured HMC in the setting mimicking IgAN.

Using similar *in vitro*culture model, we had previously demonstrated that that tumor necrosis factor-α (TNF-α) and AngII are released from mesangial cells following initial deposition of \"pathogenetic\" pIgA \[[@B3]\]. This is followed by mesangial proliferation and glomerular infiltration of immuno-competent cells. A cross-talk network initiated by TNF-α, AngII and other soluble factors orchestrates interactions between infiltrating immuno-competent cells and the resident renal cells, forming a major driving force of tubulointerstitial injury. We further demonstrate that AngII, but not Aldo, released by pIgA-activated HMC up-regulate the expression of AT2R and MR by PTEC. The increased MR expression in PTEC is readily available for the binding to Aldo, released by the pIgA-activated HMC, to initiate the downstream events of PTEC injury. Our observation of an up-regulation of MR but not 11β-HSD2 in PTEC is intriguing. Previously, it is believed that the specificity for MR to Aldo is conferred enzymatically by the cortisol-inactivating enzyme 11β-HSD2 \[[@B29],[@B30]\]. However, recent evidence has suggested that it may not be totally true as it is improbable for the intrarenal 11β-HSD2 to convert all the glucocorticoid molecules to MR-inactive metabolites with the inexhaustible supply of steroid substrate \[[@B31]\]. The current view suggests that the enzyme 11β-HSD2 does not block the glucocorticoid occupancy of MR but the ability of glucocorticoid to act as MR agonist. In the absence of the enzyme, there is intracellular redox change due to reduced generation of nicotinamide-adenine dinucleotide (NADH) from nicotinamide-adenine dinucleotide (NAD), the co-substrate for the cortisol-to-cortisone conversion \[[@B31],[@B32]\]. It has been demonstrated by patch-clamp study in isolated rabbit cardiomyocytes that under normal conditions, cortisol is an MR antagonist on the Aldo-induced transmembrane pump current. However, cortisol becomes an MR agonist, mimicking the effect of aldosterone, under redox change with instillation of oxidized glutathione \[[@B33]\]. It has been suggested that MR, which are constitutively occupied by normal glucocorticoid levels, responds to changes in intracellular redox state in tissues either expressing (e.g. vascular smooth muscle cells) \[[@B34]\] or lacking 11β-HSD2 (e.g. cardiomyocytes) \[[@B35]\]. We speculate that apart from the increased availability of MR expression to the up-regulated aldosterone release by pIgA-activated HMC in PTEC, cellular cortisol in PTEC may also act agonistically on the up-regulated MR in the absence of 11β-HSD2 under redox changes. The combined effect of aldosterone and cortisol *via*MR may eventually lead to cellular apoptosis.

Our data reveal that PTEC cultured with AngII, Aldo or IgA-HMC medium prepared from IgAN patients express increased NADPH oxidase and ROS formation. The events are associated with increased apoptosis in PTEC demonstrated by dose- and time-dependent up-regulation of cleaved PARP expression and caspase 3 activity. The primary function NADPH oxidase is to generate ROS \[[@B36],[@B37]\]. Although the NADPH oxidase was originally identified in phagocytic leukocytes, recent study discovered that this enzyme is an essential endogenous origin of cellular oxidative stress and cellular injury in other cell types \[[@B36]\]. Furthermore, ROS generated by the NADPH oxidase may also modulate many intracellular redox signal transduction pathways \[[@B36]\]. PTEC process all components of the NADPH oxidase complex \[[@B36],[@B38],[@B39]\]. The exact function of NADPH oxidase in regulating physiological and pathophysiological processes in the kidney remains unknown. Data from *in vitro*experiments have shown that NADPH oxidase-derived ROS mediate apoptosis in renal cells \[[@B39],[@B40]\]. AngII is an important *in vivo*regulator of NADPH oxidase in the kidney through activation of renal NADPH oxidase and induction of oxidative stress \[[@B38]\]. Recent data from transgenic mouse model suggest that up-regulation of NADPH oxidase-dependent ROS generation is important in mediating apoptosis in renal tubular epithelial cell induced by AngII. Apart from AngII, our present study provides novel *in vitro*data showing that Aldo also induces NADPH oxidase expression and its dependent ROS generation by PTEC. Further *in vivo*experiment is needed to validate the role of Aldo in inducing PTEC apoptosis through NADPH oxidase and ROS generation.

Blockade of the RAS with ACEI or AT1R blocker protects hypertensive and diabetic kidney injuries by inhibiting the renal NADPH \[[@B41]-[@B43]\]. Aldo also enhances NADPH oxidase activity via translocation of the cytosolic component, p47phox, to the membrane subunits by an ERK1/2-related pathway \[[@B44]\]. Aldo has also been shown to stimulate angiotensin-converting enzyme (ACE) expression which stimulates renal AngII production \[[@B45]\]. Recent clinical studies indicate that Aldo blockade may provide renoprotection by decreasing proteinuria, independent of blood pressure control. The combination of ACEI and the selective Aldo blocker, eplerenone, can provide a better renal outcome with reduction of proteinuria and kidney damage than monotherapy \[[@B24],[@B46]\]. Interestingly, treatment with eplerenone alone or combining with the ACEI reduced proteinuria more effectively than the ACEI alone in human studies \[[@B47],[@B48]\]. In DSHF rat, combined therapy with eplerenone and ACEI reduced glomerulosclerosis, proteinuria and improved renal function more effectively than monotherapy \[[@B27]\]. Based on the finding of up-regulated expression of MR and AT2R in PTEC by IgA-HMC medium from IgAN patients and AngII, we tested whether combined blockade of AT2R and MR could suppress pIgA-induced PTEC apoptosis through the glomerulo-tubular communication. Our present data confirm that blockade with PD123319 and eplererone abolishes NADPH-dependent ROS generation and apoptosis. Further *in vivo*study is needed to test whether combined AngII receptor and Aldo blockade provides a better renal outcome with reduction of proteinuria and tissue damage in IgAN.

Based on our previous studies \[[@B3],[@B4],[@B8],[@B9],[@B49]\] and the present data, a mechanistic schema summarizing the contributory role of the RAAS in glomerulo-tubular communications operating in tubulointerstitial injury in IgAN is shown in Figure [12](#F12){ref-type="fig"}.

![**Schema showing the possible role of RAAS components in the glomerulo-tubular communication operating the pathogenesis of IgAN**. Polymeric IgA from IgAN patients is capable of enhancing AngII release or Aldo synthesis through increasing the expression of ACE/ANG or CYP11B2 in HMC. The increased synthesis of AngII and Aldo up-regulates the TGF-β synthesis *via*binding to their respective receptors: AT1R and MR. Aldo is able to further up-regulate the ACE/ANG expression and AngII release in HMC whereas AngII increases the Aldo release by HMC *via*increased expression of CYP11B2. This vicious cycle involving pIgA-induced AngII and Aldo in HMC amplifies the pIgA-induced HMC damages and initiates the downstream inflammatory cascade in PTEC through the glomerulo-tubular communication. AngII released by pIgA-activated HMC up-regulates the expression of AT2R and MR by PTEC. Binding of AngII and Aldo to their respective receptors on PTEC induces cellular apoptosis through increased NADPH activity and generation of ROS. Combined blockade of AT2R and MR can prevent pIgA-induced PTEC apoptosis through these glomerulo-tubular communications.](1479-5876-9-169-12){#F12}

Conclusions
===========

Taken together, our *in vitro*data suggest that AngII and Aldo, released by pIgA1 activated HMC, are mediators for glomerulotubular crosstalk in inducing apoptosis of PTEC through NADPH dependent generation of ROS. In addition, crosstalk between AngII and Aldo could play a role in pIgA1 induced PTEC apoptosis in IgAN.
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